After the drug lowered inflammation but not heart attacks in a big Phase 3, a monitoring committee judged two follow-on trials unlikely to succeed — a setback for the “inflammation causes heart disease” strategy.
The deal brings GSK a first-in-class “antibody-targeted therapy conjugate” that hits EGFR and KRAS at once — a design meant to aim a potent KRAS blocker straight at tumors.
Hospital pharmacists and industry are jointly pushing to extend medicine barcodes down to the individual dose — a change they say could sharply cut bedside medication errors.
AtomVie has opened what it calls North America’s largest single-site radiopharmaceutical manufacturing facility — a bet on the fast-growing field of radioactive targeted therapies.
Aptar Pharma is joining Aceso Therapeutics to develop ACT-101 — an inhalable oligonucleotide that works at the RNA level, before the faulty CF protein is even built.
The amino acid, sold as a focus-and-alertness supplement, was linked to reduced life expectancy in men in a large genetic analysis — but researchers stress it doesn’t show supplements shorten life.
Medicines Discovery Catapult is funding Flip Therapeutics and Nascent Therapeutics — one reprogramming immune cells, the other restoring aging cells’ power plants.
In a 1,000-person trial across Latin America, structured exercise, diet, brain training and heart-health monitoring — with ongoing coaching — sharply outperformed basic health education.
Scientists mapped how dormant tumor cells shelter inside protective niches of immune and support cells — a hideout that may explain why cancer comes back years later.
Three lots of the hospital multi-dose vials are being pulled nationwide after reports of leaking, cracked containers and particulate contamination that could be life-threatening if injected.
Venetoclax, already used for blood cancers, pushed latently infected cells to die and cut the intact viral reservoir in SIV-infected macaques, with effects lasting months.
GTX-102 missed all its goals in a Phase 3 study for the rare disorder, wiping out a would-be blockbuster and pushing the company toward significant cost cuts.